Journal Logo

Procalcitonin: Risk Assessment in COVID-19 Bacterial Co-Infection-Sponsored by Thermo Fisher Scientific

Procalcitonin (PCT) is a biomarker widely used to assess the risk of bacterial infection and to aid in antibiotic stewardship in patients with lower respiratory tract infections (LRTI) and sepsis. PCT now also demonstrates evolving evidence as a valuable tool in current COVID-19 epidemics to aid in early identification of patients at low risk of bacterial infection on admission as well as assist in detection of bacterial co-infection in hospitalized patients.

Subscribe to this podcast using iTunes


Duration: 30:39
Emergency Medicine News 
Sherrie Smartt, RN, MSN, Medical Director of Clinical Studies and Regulatory Affairs Manager for Thermo Fisher Diagnostic Biomarkers, interviews Eric H. Gluck MD, Director of Critical Care Services at Swedish Covenant Hospital, Professor of Medicine at Finch University of Health Sciences, an author of the foundation for the MOSES trial, which expanded the procalcitonin FDA claim, and a member on PCT-Guided Antibiotic Therapy in Hospitals, and Mike Broyles, PharmD, a hospital pharmacy and laboratory director focusing on antimicrobial stewardship and consultant for a large IDN as pharmacy advisory chairman for more than 25 years, who is also on the Board for Thermo Fisher Scientific, Roche Diagnostics, bioMerieux, Fujirebio, Abbott Diagnostics, and ICNet, and a member on PCT-Guided Antibiotic Therapy in Hospitals.

Sponsored by Thermo Fisher Scientific